studi clinici

Al nido, oggi più che mai

G. Tamburlini, F. Zanetto

2020/9 — pag. 551-553 — DOI

Farmaci, sperimentazioni, registri, nei tempi dell’emergenza del coronavirus

M. Fontana, G. Zuin, A. Addis, F. Marchetti

2020/4 — pag. 232-236

Covid-19 is forcing medical doctors to deal with the urgent need to find clinical answers in an area where, unfortunately, there are still therapies with no evidence of efficacy and safety. In any case, they must make decisions and face the dilemma o...

Registrazione, rimborso e uso appropriato dei farmacinon sono sinonimi: il caso del palivizumab

A. Addis, M. Bonati, F. Marchetti

2016/8 — pag. 507-512

Respiratory syncytial virus (RSV) is a common reason for hospitalization of infants. Data from clinical trials showed that palivizumab reduced RSV hospitalization rates for premature infants. However, according to different sources of information s...

Il midazolam in soluzione transmucosa orale

F. Marchetti, G. Rametta, P. Ricciardelli

2013/5 — pag. 313-317

Oromucosal midazolam (Buccolam) has been recently approved also in Italy for the treatment of paediatric patients (aged 3 months to 5 minutes). Oromucosal midazolam was at least as effective as rectal diazepam in clinical trials in children with ...

La terapia dell’otite media acuta: quello che gli studi clinici e le Linee Guida non dicono

F. Marchetti

2011/3 — pag. 143-144

Il placebo, la condizione degli studi e l’indipendenza della ricerca

F. Marchetti

2006/6 — pag. 347-350

Vaccinazione antinfluenzale di massa in età pediatrica: quali evidenze abbiamo?

S. Di Mario et al.

2004/1 — pag. 38-46

At the beginning of the 2003-2004 influenza season a debate gained the media attention during few weeks, focusing the attention of Italian pediatricians and Italian families. Groups and associations of Italian pediatricians advocated for universal ...